Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet
Authors:
- Tomáš RoubíčekTRTomáš Roubíček
- Markéta BártlováMBMarkéta Bártlová
- Miloš MrázMMMiloš Mráz
- Zdena LacinováZLZdena Lacinová
- Denisa HaluzíkováDHDenisa Haluzíková
- Petra KaválkováPKPetra Kaválková
- Martin MatoulekMMMartin Matoulek
- Mojmír KasalickýMKMojmír Kasalický
- Martin HaluzíkMHMartin Haluzík
- 1 September 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 161 (3) , 397-404
Abstract
Objective: Macrophage inhibitory cytokine-1 (MIC-1) is a novel regulator of energy homeostasis. We explored whether alterations in MIC-1 levels contribute to metabolic disturbances in patients with obesity and/or obesity and type 2 diabetes mellitus (T2DM).Design: We measured serum MIC-1 levels and its mRNA expression in subcutaneous and visceral adipose tissue of 17 obese nondiabetic women, 14 obese women with T2DM and 23 healthy lean women. We also explored the relationship of MIC-1 with anthropometric and biochemical parameters and studied the influence of 2-week very low calorie diet (VLCD) on serum MIC-1 levels.Methods: Serum MIC-1 levels were measured by ELISA and its mRNA expression was determined by RT-PCR.Results: Both obese and T2DM group had significantly elevated serum MIC-1 levels relative to controls. T2DM group had significantly higher serum MIC-1 levels relative to obese group. Serum MIC-1 positively correlated with body weight, body fat, and serum levels of triglycerides, glucose, HbAlc, and C-reactive protein and it was inversely related to serum high-density lipoprotein cholesterol. Fat mRNA MIC-1 expression did not significantly differ between lean and obese women but it was significantly higher in subcutaneous than in visceral fat in both groups. VLCD significantly increased serum MIC-1 levels in obese but not T2DM group.Conclusion: Elevated MIC-1 levels in patients with obesity are further increased by the presence of T2DM. We suggest that in contrast to patients with cancer cachexia, increased MIC-1 levels in obese patients and diabetic patients do not induce weight loss.Keywords
This publication has 21 references indexed in Scilit:
- Influence of postprandial triglyceride-rich lipoproteins on lipid-mediated gene expression in smooth muscle cells of the human coronary arteryCardiovascular Research, 2008
- Serum macrophage inhibitory cytokine 1 in rheumatoid arthritis: A potential marker of erosive joint destructionArthritis & Rheumatism, 2007
- Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9Clinical Cancer Research, 2006
- Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer DiagnosisClinical Cancer Research, 2006
- The Propeptide Mediates Formation of Stromal Stores of PROMIC-1: Role in Determining Prostate Cancer OutcomeCancer Research, 2005
- Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control studyThe Lancet, 2002
- Characterization of Growth-Differentiation Factor 15, a Transforming Growth Factor β Superfamily Member Induced following Liver InjuryMolecular and Cellular Biology, 2000
- Expression of a novel member of the TGF-β superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissuesCell and tissue research, 1999
- Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein FamilyJournal of Biological Chemistry, 1998
- MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-β superfamilyProceedings of the National Academy of Sciences, 1997